CPRC
AZN icon

Consolidated Portfolio Review Corp’s AstraZeneca AZN Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,344
Closed -$360K – 61
2025
Q3 		$360K Sell
2,344
-23
-1% -$3.48K 0.05% 332
2025
Q2 		$331K Hold
2,367
– – 0.05% 331
2025
Q1 		$348K Sell
2,367
-250
-10% -$36.2K 0.06% 278
2024
Q4 		$343K Buy
+2,617
New +$366K 0.05% 274

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Consolidated Portfolio Review Corp's AZN Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 2,344 shares — an estimated $360K sold.

Consolidated Portfolio Review Corp first reported a position in AZN in Q4 2024 and held it in 4 quarters. The position peaked at $360K in Q3 2025. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,344 AstraZeneca shares in Q4 2025, an estimated $360K.
  • Consolidated Portfolio Review Corp first reported a position in AstraZeneca in Q4 2024 and held it in 4 quarters.
  • Consolidated Portfolio Review Corp's AstraZeneca position peaked at $360K in Q3 2025.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.